Edgar Filing: Wood Mark - Form 4

Wood Mark Form 4 November 2	25, 2011								OMB AF	PROVAL	
	• • UNITED	STATES S			AND EX , D.C. 2(ANGE CO	OMMISSION	OMB Number:	3235-0287	
Check the check	aar			U	·				Expires:	January 31, 2005	
In horologer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Estimated average subject to Section 16. SECURITIES Estimated average Form 4 or Form 5 Section 16(a) of the Securities Exchange Act of 1934, Estimated average obligations Filed pursuant to Section 16(a) of the Securities Exchange Act of 1935 or Section Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							verage				
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Wood Mark			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				8	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 11/22/2011					Director 10% Owner XOfficer (give titleOther (specify below) below) VP, Human Resources			
NOVATO,		4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
(City)	(State)	(Zip)	<i></i>			a		Person			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		l 3 pate, if T (/Year) (8. Fransactic Code Instr. 8)		ties A sed of	cquired (A) (D)	ired, Disposed of, 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	y Owned 7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/22/2011 <u>(1)</u>	11/22/201		M	83	A	\$ 17.86	20,717	D		
Common Stock	11/22/2011 <u>(1)</u>	11/22/201	1	М	938	A	\$ 14.39	21,655	D		
Common Stock	11/22/2011 <u>(1)</u>	11/22/201	1	М	834	А	\$ 21.51	22,489	D		
Common Stock	11/22/2011 <u>(1)</u>	11/22/201	1	S	1,855	D	\$ 32.1817 (2)	20,634	D		

Edgar Filing: Wood Mark - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to bu) Common Stock	\$ 17.86	11/22/2011 <u>(1)</u>	11/22/2011	М	83	06/17/2009 <u>(3)</u>	12/16/2018	Common Stock	83
Stock Option (right to buy) Common Stock	\$ 14.39	11/22/2011 <u>(1)</u>	11/22/2011	М	938	11/12/2009 <u>(4)</u>	05/11/2019	Common Stock	938
Stock Option (right to buy) Common Stock	\$ 21.51	11/22/2011 <u>(1)</u>	11/22/2011	М	834	11/12/2010 <u>(5)</u>	05/11/2020	Common Stock	834

Reporting Owners

Reporting Owner Name / Address	Kelationships					
	Director	10% Owner	Officer	Other		
Wood Mark C/O BIOMARIN PHARMACEUTICAL INC.			VP, Human Resources			

105 DIGITAL DRIVE NOVATO, CA 94949

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact

11/25/2011

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading plan executed on August 20, 2011.

The price in Column 4 is a weighted average price. The prices actually received ranged from \$31.29 to \$33.11. The reporting person will(2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

- (3) Original option grant vests 6/48th on June 17, 2009 and 1/48th each on the 17th of each month thereafter.
- (4) Original option grant vests 6/48th on November 12, 2009 and 1/48th each on the 12th of each month thereafter.
- (5) Original option grant vests 6/48th on November 12, 2010 and 1/48th each on the 12th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.